What's in LG Life Sciences's pipeline?

LG Life Sciences has 39 drugs in our index: 6 marketed, 0 filed, 14 in Phase 3, 6 in Phase 2, 13 in Phase 1.

Which companies overlap with LG Life Sciences's portfolio?

Top competitors by shared drug class: Sanofi, Merck Sharp & Dohme LLC, GlaxoSmithKline, Novartis, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lg-life-sciences.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

LG Life Sciences — Portfolio Competitive Intelligence Brief

LG Life Sciences pipeline: 6 marketed, 0 filed, 14 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 14 Phase 3 6 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Sancuso patch	Sancuso patch	marketed	5-HT3 receptor antagonist	5-HT3 receptor	Oncology
Menopur® Inj.	Menopur® Inj.	marketed	Gonadotropin	FSH receptor and LH receptor	Reproductive Medicine / Fertility
Enbrel	Enbrel	marketed		Tumor necrosis factor	Oncology
Kytril inj.+Kytril tab.	Kytril inj.+Kytril tab.	marketed	5-HT3 receptor antagonist	5-HT3 receptor	Oncology, Anesthesia
Zofran inj.+Zofran tab.	Zofran inj.+Zofran tab.	marketed	5-HT3 receptor antagonist	5-HT3 receptor	Oncology, Gastroenterology, Anesthesia
IVF-M HP Inj.	IVF-M HP Inj.	marketed	Gonadotropin (recombinant FSH)	FSH receptor (FSHR)	Reproductive Medicine / Fertility
LBVH0101 (Hib vaccine)	LBVH0101 (Hib vaccine)	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)	Immunology
Hiberix™ Vaccine	Hiberix™ Vaccine	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)	Immunology / Infectious Disease
Hyruan Plus	Hyruan Plus	phase 3	Viscosupplement	Hyaluronic acid receptor (CD44)	Orthopedics / Rheumatology
LBAL	LBAL	phase 3
LBEC0101	LBEC0101	phase 3
Placebo to Linagliptin	Placebo to Linagliptin	phase 3	DPP-4 inhibitor	DPP-4	Diabetes

Therapeutic area mix

Diabetes · 4
Other · 3
Reproductive Medicine / Fertility · 2
Oncology · 2
Diabetes and Cardiovascular · 1
Oncology, Anesthesia · 1
Oncology, Gastroenterology, Anesthesia · 1
Orthopedics / Rheumatology · 1
Immunology · 1
Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Novartis · 3 shared drug classes
Takeda · 3 shared drug classes
Eurofarma Laboratorios S.A. · 2 shared drug classes
JW Pharmaceutical · 2 shared drug classes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for LG Life Sciences:

Cite this brief

Drug Landscape (2026). LG Life Sciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lg-life-sciences. Accessed 2026-05-14.